Effect of Human Papillomavirus (HPV) Vaccination on HPV Infection and Recurrence of HPV Related Disease After Local Surgical Treatment: A Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Dec 31

PMID 39739895

Authors

Qinxue Cao

Yantao Hou

Chaoyang Wang

Juntao Yin

Affiliations

Soon will be listed here.

Abstract

Background: The prophylactic vaccines available to protect against infections by human papillomavirus (HPV) are well tolerated and highly immunogenic. This systematic review and meta-analysis aimed to explore the efficacy of HPV vaccination on the risk of HPV infection and recurrent diseases related to HPV infection in individuals undergoing local surgical treatment.

Methods: A literature search was performed using PubMed/MEDLINE, Embase, the Cochrane Library, Scopus, Web of Science, and bioRxiv/medRxiv from inception to July 15, 2024. Randomized controlled trials (RCTs) reporting the effect of HPV vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment vs no HPV vaccination were included. The primary outcome measure was risk of recurrence cervical high-grade squamous intraepithelial lesion (HSIL) after local surgical treatment, with follow-up as reported by individual studies. Included studies were assessed for risk of bias using the Revised Cochrane risk-of-bias (RoB 2.0 tool). Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated. No restrictions were applied on language, the date of publication, age, sex, and country. All analyses were carried out using the Review Manager 5 software (version 5.4).

Results: Eight RCTs (n = 3068) met the inclusion criteria. The risk of cervical HSIL recurrence was not reduced in individuals who were vaccinated compared with those who were not vaccinated (RR 0.92, 95% CI: 0.66-1.27; I2 = 40%). However, HPV vaccination reduced the risk of recurrence of cervical HSIL related to the HPV types HPV16/18, but uncertainty was large (RR 0.57, 95% CI: 0.18-1.84; I2 = 29%).

Conclusions: Adjuvant HPV vaccination after surgical excision is not associated with a reduced risk of recurrent HSIL overall or a reduced risk of recurrent lesions caused by the most oncogenic strains (HPV16/18). Therefore, HPV vaccination should not be considered for adjuvant treatment in patients undergoing surgical excision.

References

Cho J, Kim E, Kim J, Shin J, Kim E, Park J . Effect of the human papillomavirus vaccine on the risk of genital warts: a nationwide cohort study of Korean adolescent girls. Epidemiol Health. 2024; 46:e2024040. PMC: 11369562. DOI: 10.4178/epih.e2024040. View

Lichter K, Krause D, Xu J, Tsai S, Hage C, Weston E . Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. Obstet Gynecol. 2020; 135(5):1070-1083. DOI: 10.1097/AOG.0000000000003833. View

Petras M, Dvorak V, Lomozova D, Macalik R, Neradova S, Dlouhy P . Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression. Sex Transm Infect. 2023; 99(8):561-570. PMC: 10715477. DOI: 10.1136/sextrans-2023-055793. View

Sterne J, Hernan M, Reeves B, Savovic J, Berkman N, Viswanathan M . ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. PMC: 5062054. DOI: 10.1136/bmj.i4919. View

Alouini S, Pichon C . Therapeutic Vaccines for HPV-Associated Cervical Malignancies: A Systematic Review. Vaccines (Basel). 2024; 12(4). PMC: 11054545. DOI: 10.3390/vaccines12040428. View

Di Donato V, Caruso G, Bogani G, Cavallari E, Palaia G, Perniola G . HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis. Vaccines (Basel). 2022; 10(2). PMC: 8879645. DOI: 10.3390/vaccines10020239. View

Goldstone S, Giuliano A, Palefsky J, Lazcano-Ponce E, Penny M, Cabello R . Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2021; 22(3):413-425. DOI: 10.1016/S1473-3099(21)00327-3. View

Giannini A, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E . Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization. Vaccines (Basel). 2023; 11(3). PMC: 10051663. DOI: 10.3390/vaccines11030698. View

Arbyn M, Redman C, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem-Maghami S . Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017; 18(12):1665-1679. DOI: 10.1016/S1470-2045(17)30700-3. View

10.

Rebolj M, Pesola F, Mathews C, Mesher D, Soldan K, Kitchener H . The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. Br J Cancer. 2022; 127(2):278-287. PMC: 9296648. DOI: 10.1038/s41416-022-01791-w. View

11.

Sand F, Kjaer S, Frederiksen K, Dehlendorff C . Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2019; 147(3):641-647. DOI: 10.1002/ijc.32752. View

12.

Kalliala I, Athanasiou A, Veroniki A, Salanti G, Efthimiou O, Raftis N . Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol. 2020; 31(2):213-227. PMC: 7479506. DOI: 10.1016/j.annonc.2019.11.004. View

13.

Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J . Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front Cell Infect Microbiol. 2022; 12:909223. PMC: 9289603. DOI: 10.3389/fcimb.2022.909223. View

14.

Shing J, Hu S, Herrero R, Hildesheim A, Porras C, Sampson J . Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022; 23(7):940-949. PMC: 9255557. DOI: 10.1016/S1470-2045(22)00291-1. View

15.

Athanasiou A, Veroniki A, Efthimiou O, Kalliala I, Naci H, Bowden S . Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis. Lancet Oncol. 2022; 23(8):1097-1108. PMC: 9630146. DOI: 10.1016/S1470-2045(22)00334-5. View

16.

Tainio K, Athanasiou A, Tikkinen K, Aaltonen R, Cardenas J, Hernandes . Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018; 360:k499. PMC: 5826010. DOI: 10.1136/bmj.k499. View

17.

Garland S, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow S . Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer. 2016; 139(12):2812-2826. PMC: 5412942. DOI: 10.1002/ijc.30391. View

18.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

19.

Joura E, Garland S, Paavonen J, Ferris D, Perez G, Ault K . Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012; 344:e1401. PMC: 3314184. DOI: 10.1136/bmj.e1401. View

20.

Kang W, Choi H, Kim S . Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?. Gynecol Oncol. 2013; 130(2):264-8. DOI: 10.1016/j.ygyno.2013.04.050. View